• 1
    Inman WHW. Postmarketing surveillance of adverse drug reactions in general practice; II: Prescription-event monitoring at the University of Southampton. BMJ 1981;282:12167.
  • 2
    Rawson NSB, Pearce GL, Inman WHW. Prescription-event monitoring: methodology and recent progress. J Clin Epidemiol 1990; 43:50922.
  • 3
    Mann RD. Prescription-event monitoring: its role in ensuring new drug safety. Prescriber 1996;7(5):1024.
  • 4
    Wilton LV, Pearce GL, Mann RD. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Br J Clin Pharmacol 1996;41:27784.
  • 5
    Schmidt D, Kramer G. The new anticonvulsant drugs: implications for avoidance of adverse effects. Drug Safety 1994;11(6):42231.
  • 6
    Brodie MJ, Richens A, Yuen A. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:4769.
  • 7
    Drug treatment of epilepsy. Drug Ther Bull 1994;32(6):458.
  • 8
    ABPI data sheet compendium 19956. Datapharm Publications Limited, pp 19335.
  • 9
    Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333(24):16007.
  • 10
    Committee on Safety of Medicines. Reminder: Iamotrigine (Lamictal) and serious skin reactions. Curr Probl Pharmacovigilance 1996;22:12.
  • 11
    Price E, Venables P. Drug-induced lupus. Drug Safety 1995;12(4):28390.
  • 12
    Brodie M. Established anticonvulsants and treatment of refractory epilepsy. Lancet 1990;336:3504.
  • 13
    Hawkins D. Epilepsy: protecting the mother and her baby. Prescriber 1996;7(10):1924.